An open randomized comparative study of the effect of goserelin depot and danazol in the treatment of endometriosis. Zoladex Endometriosis Study Team.

Shaw RW

Fertility and sterility1 Aug 1992Cited by 82 (Europe PMC)

PMID1386029DOI10.1016/s0015-0282(16)55205-4PepBankPUB-01386029

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialOther
In women with endometriosis, withdrawal was lower with goserelin at 6.4% than danazol at 20.4%.
In plain wordsIn women with endometriosis, fewer patients stopped treatment with goserelin at 6.4% than with danazol at 20.4%.
Peptide
Goserelin
Outcome
DecreaseTreatment withdrawal
Study
n = 307
Comparator
Danazol
Outcome group
Treatment adherence and retention · Reproductive and sexual health
Studied dose
3.6 mg monthly · subcutaneous · 24 weeksAs given in this study (human).
Measurements
Withdrawal
6.4%
goserelin
Withdrawal
20.4%
danazol
Source sentences
Summary
Significantly fewer patients randomized to goserelin (6.4%) withdrew during treatment compared with 20.4% randomized to danazol (P less than 0.05).
3 context sentences(design, population, supporting numbers)
Summary · context
Open, randomized comparative trial.
Summary · context
A total of 307 patients with laparoscopically diagnosed endometriosis were randomized to goserelin (n = 204) or danazol (n = 103); 249 patients underwent second look laparoscopy (175 received goserelin and 74 danazol) and were analyzed for efficacy.
Summary · context
A 3.6-mg depot of goserelin monthly subcutaneously or oral danazol 200 mg three times a day administered for 24 weeks.
Report a problemFND-0138602901
02HumanRandomized controlled trialSafety outcome
In women with endometriosis, hypoestrogenic side effects were more common with goserelin than danazol.
In plain wordsIn women with endometriosis, low-estrogen side effects were more common with goserelin than danazol.
Peptide
Goserelin
Outcome
IncreaseHypoestrogenic side effects
Study
n = 307
Comparator
Danazol
Outcome group
Adverse events · Reproductive and sexual health
Studied dose
3.6 mg monthly · subcutaneous · 24 weeksAs given in this study (human).
Source sentences
Summary
Hypoestrogenic side effects were more common in those receiving goserelin, particularly hot flushes, but anabolic/androgenic side effects of weight gain and muscle cramps were more common in those receiving danazol.
3 context sentences(design, population, supporting numbers)
Summary · context
Open, randomized comparative trial.
Summary · context
A total of 307 patients with laparoscopically diagnosed endometriosis were randomized to goserelin (n = 204) or danazol (n = 103); 249 patients underwent second look laparoscopy (175 received goserelin and 74 danazol) and were analyzed for efficacy.
Summary · context
A 3.6-mg depot of goserelin monthly subcutaneously or oral danazol 200 mg three times a day administered for 24 weeks.
Report a problemFND-0138602905
03HumanRandomized controlled trialSafety outcome
In women with endometriosis, hypoestrogenic side effects, particularly hot flushes, were more common with goserelin than danazol.
In plain wordsIn women with endometriosis, low-estrogen side effects, particularly hot flushes, were more common with goserelin than danazol.
Peptide
Goserelin
Outcome
IncreaseHot flushes
Study
n = 307
Comparator
Danazol
Outcome group
Adverse events · Reproductive and sexual health
Studied dose
3.6 mg monthly · subcutaneous · 24 weeksAs given in this study (human).
Source sentences
Summary
Hypoestrogenic side effects were more common in those receiving goserelin, particularly hot flushes, but anabolic/androgenic side effects of weight gain and muscle cramps were more common in those receiving danazol.
3 context sentences(design, population, supporting numbers)
Summary · context
Open, randomized comparative trial.
Summary · context
A total of 307 patients with laparoscopically diagnosed endometriosis were randomized to goserelin (n = 204) or danazol (n = 103); 249 patients underwent second look laparoscopy (175 received goserelin and 74 danazol) and were analyzed for efficacy.
Summary · context
A 3.6-mg depot of goserelin monthly subcutaneously or oral danazol 200 mg three times a day administered for 24 weeks.
Report a problemFND-0138602906
04HumanRandomized controlled trialSafety outcome
In women with endometriosis, weight gain was less common with goserelin than danazol.
In plain wordsIn women with endometriosis, weight gain was less common with goserelin than danazol.
Peptide
Goserelin
Outcome
DecreaseWeight gain
Study
n = 307
Comparator
Danazol
Outcome group
Adverse events · Metabolic and weight
Studied dose
3.6 mg monthly · subcutaneous · 24 weeksAs given in this study (human).
Source sentences
Summary
Hypoestrogenic side effects were more common in those receiving goserelin, particularly hot flushes, but anabolic/androgenic side effects of weight gain and muscle cramps were more common in those receiving danazol.
2 context sentences(design, population, supporting numbers)
Summary · context
Open, randomized comparative trial.
Summary · context
A 3.6-mg depot of goserelin monthly subcutaneously or oral danazol 200 mg three times a day administered for 24 weeks.
Report a problemFND-0138602907
05HumanRandomized controlled trialSafety outcome
In women with endometriosis, muscle cramps were less common with goserelin than danazol.
In plain wordsIn women with endometriosis, muscle cramps were less common with goserelin than danazol.
Peptide
Goserelin
Outcome
DecreaseMuscle cramps
Study
n = 307
Comparator
Danazol
Outcome group
Adverse events · Musculoskeletal
Studied dose
3.6 mg monthly · subcutaneous · 24 weeksAs given in this study (human).
Source sentences
Summary
Hypoestrogenic side effects were more common in those receiving goserelin, particularly hot flushes, but anabolic/androgenic side effects of weight gain and muscle cramps were more common in those receiving danazol.
2 context sentences(design, population, supporting numbers)
Summary · context
Open, randomized comparative trial.
Summary · context
A 3.6-mg depot of goserelin monthly subcutaneously or oral danazol 200 mg three times a day administered for 24 weeks.
Report a problemFND-0138602908
06HumanRandomized controlled trialEfficacy outcome
In women with endometriosis, post-treatment visible deposits did not differ between goserelin and danazol.
In plain wordsIn women with endometriosis, visible deposits after treatment did not differ between goserelin and danazol.
Peptide
Goserelin
Outcome
No significant changeVisible endometriosis deposits versus danazol
Study
n = 249
Comparator
Danazol
Outcome group
Organ injury · Reproductive and sexual health
Studied dose
3.6 mg monthly · subcutaneous · 24 weeksAs given in this study (human).
Source sentences
Summary
There were significantly reduced visible deposits of endometriosis found post-treatment (P less than 0.0001) within each group but no differences between the treatments.
3 context sentences(design, population, supporting numbers)
Summary · context
Open, randomized comparative trial.
Summary · context
A total of 307 patients with laparoscopically diagnosed endometriosis were randomized to goserelin (n = 204) or danazol (n = 103); 249 patients underwent second look laparoscopy (175 received goserelin and 74 danazol) and were analyzed for efficacy.
Summary · context
A 3.6-mg depot of goserelin monthly subcutaneously or oral danazol 200 mg three times a day administered for 24 weeks.
Report a problemFND-0138602903
07HumanNon-randomized trialEfficacy outcome
In women with endometriosis, visible deposits significantly decreased after goserelin treatment versus baseline.
In plain wordsIn women with endometriosis, visible deposits decreased after goserelin compared with pretreatment values.
Peptide
Goserelin
Outcome
DecreaseVisible endometriosis deposits versus baseline
Study
n = 175
Outcome group
Organ injury · Reproductive and sexual health
Studied dose
3.6 mg monthly · subcutaneous · 24 weeksAs given in this study (human).
Source sentences
Summary
There were significantly reduced visible deposits of endometriosis found post-treatment (P less than 0.0001) within each group but no differences between the treatments.
3 context sentences(design, population, supporting numbers)
Summary · context
Open, randomized comparative trial.
Summary · context
A total of 307 patients with laparoscopically diagnosed endometriosis were randomized to goserelin (n = 204) or danazol (n = 103); 249 patients underwent second look laparoscopy (175 received goserelin and 74 danazol) and were analyzed for efficacy.
Summary · context
A 3.6-mg depot of goserelin monthly subcutaneously or oral danazol 200 mg three times a day administered for 24 weeks.
Report a problemFND-0138602902
08HumanNon-randomized trialEfficacy outcome
In women with endometriosis, mean total subjective symptom scores remained significantly below entry values at 24 weeks after goserelin treatment.
In plain wordsIn women with endometriosis, symptom scores remained below pretreatment values at 24 weeks after goserelin treatment.
Peptide
Goserelin
Outcome
DecreaseSubjective symptom scores after treatment
Study
n: not reported in source
Outcome group
Organ injury · Reproductive and sexual health
Studied dose
3.6 mg monthly · subcutaneous · 24 weeksAs given in this study (human).
Source sentences
Summary
The mean total subjective symptoms scores remained significantly less than entry at 24 weeks post-treatment (P less than 0.05).
4 context sentences(design, population, supporting numbers)
Summary · context
Open, randomized comparative trial.
Summary · context
A total of 307 patients with laparoscopically diagnosed endometriosis were randomized to goserelin (n = 204) or danazol (n = 103); 249 patients underwent second look laparoscopy (175 received goserelin and 74 danazol) and were analyzed for efficacy.
Summary · context
A 3.6-mg depot of goserelin monthly subcutaneously or oral danazol 200 mg three times a day administered for 24 weeks.
Summary · context
The monthly administered 3.6-mg depot preparation of goserelin was highly effective at inducing resolution of endometriotic implants and relieving the symptoms of endometriosis with prevention of their return during 24 weeks follow-up in the majority of patients.
Report a problemFND-0138602904

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.